On February 20, 2024, Timothy Pitoniak informed Issuer Direct Corporation (the “ Company ”) of his resignation as Chief Financial Officer of the Company, effective March 8, 2024 (the “ Effective Date” ).
Appointed
(interim)
Steve Knerr
interim Principal Accounting Officer and interim Chief Financial Officer
the Board intends to appoint Steve Knerr, the Company’s current Vice President of Finance and Controller, as its interim Principal Accounting Officer and interim Chief Financial Officer.
On February 23, 2024, the Board appointed Eric Mosser, a current Senior Advisor to the Company and the Chief Executive Officer of Kaival International Brands, LLC, a wholly owned subsidiary of the Company, as the Company’s President and Interim Chief Executive Officer, to serve in such capacity until a successor is duly appointed and approved by the Board.
On February 22, 2024, Barry M. Hopkins, the Interim Chief Executive Officer, President, and Director of the Company, provided written notice to the Company’s Board of Directors (the “Board”) of his resignation, effectively immediately.
On February 20, 2024, Thomas Metzler, the Chief Financial Officer, Secretary and Treasurer of the Company, provided written notice to the Company’s Board of his resignation, effectively immediately.
On February 22, 2024, Envista Holdings Corporation (the “Company”) and Amir Aghdaei, the President and Chief Executive Officer of the Company, entered into a transition letter agreement (the “Transition Agreement”), setting forth the terms of Mr. Aghdaei’s anticipated transition from his position as the Company’s President and Chief Executive Officer.
Appointed
R. Ryan Richards
Executive Vice President and Chief Financial Officer of the Company
ZION ·
ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/
Effective
2024-04-01
Filed
February 23, 2024, 6:59 PM ET
R. Ryan Richards will succeed Mr. Burdiss as Executive Vice President and Chief Financial Officer of the Company, having previously served as the Company’s Senior Vice President and Corporate Controller since 2021.
unanimously appointed Jackson Hsieh to fill the newly created vacancy, effective concurrently with his appointment to the role of Chief Executive Officer and President on March 1, 2024.
Appointed
(interim)
Forrest Hoffmaster
interim Chief Executive Officer
Medicine Man Technologies, Inc.
Effective
2024-02-21
Filed
February 23, 2024, 6:59 PM ET
On February 21, 2024 (“Appointment Date”), the Board appointed Forrest Hoffmaster, the Company’s Chief Financial Officer, as interim Chief Executive Officer of the Company.
Departed
Nirup Krishnamurthy
Chief Executive Officer
Medicine Man Technologies, Inc.
Effective
2024-02-20
Successor
Forrest Hoffmaster
Filed
February 23, 2024, 6:59 PM ET
On February 20, 2024, the Company received notice of the resignation of Nirup Krishnamurthy as a member of the Company’s board of directors (the “Board”) and Chief Executive Officer of the Company
appointed Kimberly A. Fields, currently the Company’s President and Chief Operating Officer, to serve as President and Chief Executive Officer of the Company, effective as of July 1, 2024.
Departed
Stephen T. Wills
Chief Financial Officer
Cactus Acquisition Corp. 1 Ltd
Effective
2024-02-23
Filed
February 23, 2024, 6:59 PM ET
the following officers submitted the resignation of their respective offices: Ofer Gonen as Chief Executive Officer, and Stephen T. Wills as Chief Financial Officer.
Departed
Ofer Gonen
Chief Executive Officer
Cactus Acquisition Corp. 1 Ltd
Effective
2024-02-23
Filed
February 23, 2024, 6:59 PM ET
the following officers submitted the resignation of their respective offices: Ofer Gonen as Chief Executive Officer, and Stephen T. Wills as Chief Financial Officer.
Role change
Jason Dubinsky
principal accounting officer (in addition to Chief Financial Officer)
the Company designated Jason Dubinsky (age 50) as principal accounting officer, in addition to his current role as Chief Financial Officer (and principal financial officer) of the Company.
On February 16, 2024, the Company and Mr. Charles Scheiwe agreed to the stepping down of Mr. Scheiwe as the Company’s Chief Financial Officer and Secretary, including all positions with the Company and Flux Power, Inc., a wholly-owned subsidiary of the Company (“Flux”) and transitioning to a consultant for the Company (“the “Transition”), effective March 1, 2024 (the “Separation Date”).
On February 22, 2024, as a result of Mr. Scheiwe’s stepping down in connection with the Transition, the Board appointed Mr. Kevin S. Royal as Chief Financial Officer and Corporate Secretary, to be effective March 4, 2024.
Departed
Richard A. Fair
President and Chief Executive Officer
BELLICUM PHARMACEUTICALS, INC
Effective
2024-02-23
Successor
Dave Maggio
Filed
February 23, 2024, 6:59 PM ET
Mr. Richard A. Fair resigned as President and Chief Executive Officer of the Company
Appointed
Dave Maggio
Chief Executive Officer
BELLICUM PHARMACEUTICALS, INC
Effective
2024-02-23
Filed
February 23, 2024, 6:59 PM ET
the Board appointed Dave Maggio to the position of Chief Executive Officer
On February 20, 2024, Christopher Meyer, the Company’s Chief Financial Officer notified the Company of his intention to retire from the Company in 2024.
On February 22, 2024, American Homes 4 Rent (the “Company”) announced that David P. Singelyn, the Company’s Chief Executive Officer, had notified the Board of Trustees (the “Board”) of the Company of his intent to retire.
the Board had appointed Bryan Smith, the Company’s Chief Operating Officer, as the new Chief Executive Officer of the Company, effective upon Mr. Singelyn’s retirement
On February 20, 2024 (the “Separation Date”), Salarius Pharmaceuticals, Inc. (the “Company”) entered into a separation and release agreement (the “Separation Agreement”) with David J. Arthur, the Company’s President and Chief Executive Officer, which provides for Mr. Arthur’s separation of employment, effective as of the Separation Date.
Appointed
(interim)
Mr. Forelle
interim consulting CEO
First Capital Real Estate Trust Inc
Effective
2020-07-01
Filed
February 23, 2024, 6:59 PM ET
In July 2020, Mr. Forelle was appointed interim consulting CEO reporting to the board.
Role change
P. Cameron Hyzer
Chief Financial Officer and Principal Accounting Officer
Effective February 26, 2024, P. Cameron Hyzer, who has served as ZoomInfo’s Chief Financial Officer since 2018, will assume the additional role of principal accounting officer.
On February 19, 2024, Mark W. Smith informed Helmerich & Payne, Inc. (the “Company”) that he will retire from his position as Senior Vice President and Chief Financial Officer of the Company effective August 15, 2024 or such earlier date as agreed to with the Company (the “Transition Date”).
On February 21, 2024, the Board of Directors (the “Board”) of MSA Safety Incorporated (the “Company”) elected Steven C. Blanco as Chief Executive Officer, to be effective May 10, 2024.
On February 19, 2024, Gain Therapeutics, Inc. (the “Company”) received notice of the resignation of C. Evan Ballantyne as the Company’s Chief Financial Officer, and all other positions held at the Company, to be effective March 1, 2024.
On February 22, 2024, Flywire Corporation (“Flywire”) announced that Cosmin Pitigoi will join Flywire as Chief Financial Officer and as its principal financial and principal accounting officer, effective March 4, 2024
Departed
Robert Noreck
Chief Financial Officer
BRIGHTCOVE INC
Effective
2024-05-31
Filed
February 22, 2024, 6:59 PM ET
On February 21, 2024, Robert Noreck, the Company's Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer (collectively, “CFO”), notified the Company of his intent to resign as CFO, effective as of the earlier of May 31, 2024 and the appointment of a successor CFO (such date, the “Transition Date”).
Synlogic, Inc. (the “ Company ”) and Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer, agreed that Dr. Brennan’s employment with the Company will terminate effective March 9, 2024
Appointed
Khairul Azmi Bin Ismaon
Chief Executive Officer
EVe Mobility Acquisition Corp
Filed
February 22, 2024, 6:59 PM ET
Khairul Azmi Bin Ismaon , age 41, serves as our Chief Executive Officer and one of our directors.
Appointed
Dr. Ulf Henning Richter
Chief Financial Officer
EVe Mobility Acquisition Corp
Filed
February 22, 2024, 6:59 PM ET
Dr. Ulf Henning Richter , age 44, serves as our Chief Financial Officer.
Appointed
Jian-Meng Yang
Chief Executive Officer
Arculus System Co., Ltd.
Filed
February 22, 2024, 6:59 PM ET
Jian-Meng Yang was appointed as Chief Executive Officer, Treasurer and Secretary, and Director of the Company.
announced Michael G. Rippey's retirement as Chief Executive Officer (“ CEO ”) and his resignation from the Company's Board of Directors (the “ Board ”), effective May 15, 2024.
On February 22, 2024, the Company announced that Jason Alger, age 40, the Company’s Chief Accounting Officer and principal accounting officer, will assume the role of Chief Financial Officer and principal financial officer of the Company, effective March 1, 2024.
On February 16, 2024, Bryan Hunt informed the board of directors of the Company (the Board) of, and on February 20, 2024, the Board accepted, his resignation as the Company's Chief Financial Officer and principal financial officer, effective March 1, 2024.
On February 19, 2024, Tom Fitzgerald notified the Company of his decision to retire as the Company’s Chief Financial Officer (“CFO”), effective as of September 1, 2024.
Mr. Trepp, who, prior to the Effective Date, served as President and Chief Executive Officer of the Company, will continue to serve as Chief Executive Officer of the Company after the Effective Date.
Michael McMullen, President and Chief Executive Officer (“CEO”) of Agilent Technologies, Inc. (the “Company” or “Agilent”), notified the Company that he will retire as President and CEO of the Company and as a member of the Company’s Board of Directors (“Board”) on May 1, 2024.
Mr. Teno will succeed David Willetts, who resigned as President and Chief Executive Officer of the Company and as a member of the Board, effective on the Effective Date.
On February 21, 2024, the Company announced the appointment of Andrew J. Teno as President and Chief Executive Officer of the Company and of Icahn Enterprises G.P. Inc. (“Icahn Enterprises GP”), the general partner of the Company and Icahn Enterprises Holdings L.P., effective as of February 21, 2024 (the “Effective Date”).
On February 20, 2024, Glendon E. French resigned as President and Chief Executive Officer of Pulmonx Corporation (the “Company”), effective as of March 15, 2024
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.